I-BET432
I-BET432 is a BET inhibitor. I-BET432 inhibits BRD4 N-terminal bromodomain (BD1) and the C-terminal bromodomain (BD2) with pIC50 values of 7.5 and 7.2, respectively. I-BET432 can be used as an oral candidate quality molecule for the research of multiple oncology and inflammatory diseases[1].
Product Specifications
UNSPSC
12352005
Target
Epigenetic Reader Domain
Type
Reference compound
Related Pathways
Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/i-bet432.html
Solubility
10 mM in DMSO
Smiles
O=C1N(C)C=C(C2=CN(C)N=C2)C3=CC([C@@H](O)CO)=CC=C3[C@H]1C
Molecular Formula
C18H21N3O3
Molecular Weight
327.38
References & Citations
[1]Humphreys PG, et al. Identification and Optimization of a Ligand-Efficient Benzoazepinone Bromodomain and Extra Terminal (BET) Family Acetyl-Lysine Mimetic into the Oral Candidate Quality Molecule I-BET432. J Med Chem. 2022 Nov 24;65 (22) :15174-15207.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
LY426640 100 µg
CAPON (NOS1AP) (NM_001126060) Human Over-expression Lysate
Sign In for Pricing
View Details 
